Annual report pursuant to Section 13 and 15(d)

Document and Entity Information

Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Apr. 20, 2023
Dec. 30, 2022
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Registrant Name GRAPHITE BIO, INC.    
Entity Central Index Key 0001815776    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Incorporation State Country Code DE    
Entity Address Address Line1 201 Haskins Way    
Entity Address, Address Line Two Suite 210    
Entity Address City Or Town South San Francisco    
Entity Address State Or Province CA    
Entity Address Postal Zip Code 94080    
City Area Code 650    
Local Phone Number 484-0886    
Entity File Number 001-40532    
Entity Tax Identification Number 84-4867570    
Security12b Title Common Stock, par value $0.00001 per share    
Trading Symbol GRPH    
Security Exchange Name NASDAQ    
Document Annual Report true    
Document Transition Report false    
Entity Public Float     $ 66.1
Entity Common Stock, Shares Outstanding   58,220,434  
Auditor Name Deloitte & Touche LLP    
Auditor Location San Francisco, CA    
Auditor Firm ID 34    
Amendment Description This Amendment No. 1 (“Amendment No. 1”) to the Annual Report on Form 10-K of Graphite Bio, Inc. (the “Company,” “we,” “our” or “us”) for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission (the “SEC”) on March 20, 2023 (the “Original Annual Report”), is being filed solely to include in the Original Annual Report the information required by Part III (Items 10, 11, 12, 13 and 14) of Form 10-K. Because the Company has determined that it will not file its definitive proxy statement within 120 days following the last day of its last fiscal year, the Company is providing Items 10, 11, 12, 13, and 14 of Part III of Form 10-K in this Amendment No. 1.This Amendment No. 1 amends and restates in their entirety Items 10 through 14 of the Original Annual Report. As required by Rule 12b-15 under the Securities and Exchange Act of 1934, as amended, new certificates of our Chief Executive Officer and Chief Financial Officer are being filed as exhibits to this Amendment No. 1. Accordingly, Item 15(a)(3) of Part IV is amended to include the currently dated certifications as exhibits. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. In addition, because no financial statements are included in this Amendment No. 1, new certifications of the Company’s Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are not required to be included with Amendment No. 1.Except as otherwise expressly noted herein, this Amendment No. 1 does not amend any other information set forth in the Original Annual Report, and we have not updated disclosures contained therein to reflect any events that occurred at a date subsequent to the date of the filing of the Original Annual Report. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Annual Report and our other filings with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No. 1 have the meanings given to them in the Original Annual Report.